Evaxion Biotech A/S (NASDAQ:EVAX) Sees Significant Growth in Short Interest

Evaxion Biotech A/S (NASDAQ:EVAX) was the recipient of a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 86,700 shares, an increase of 48.0% from the February 13th total of 58,600 shares. Based on an average daily volume of 2,250,000 shares, the short-interest ratio is presently 0.0 days. Currently, 8.2% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Lake Street Capital dropped their price target on shares of Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Evaxion Biotech A/S in a research report on Thursday, February 20th.

Hedge Funds Weigh In On Evaxion Biotech A/S

An institutional investor recently raised its position in Evaxion Biotech A/S stock. Invst LLC boosted its stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) by 16.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,400 shares of the company’s stock after purchasing an additional 7,200 shares during the quarter. Invst LLC owned about 4.31% of Evaxion Biotech A/S worth $43,000 at the end of the most recent quarter. Institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Stock Performance

Evaxion Biotech A/S stock traded down $0.01 during mid-day trading on Friday, reaching $1.78. The company’s stock had a trading volume of 44,601 shares, compared to its average volume of 595,249. The firm has a market cap of $2.09 million, a price-to-earnings ratio of -1.23 and a beta of -0.25. The business has a 50 day moving average price of $2.86 and a 200-day moving average price of $8.19. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. Evaxion Biotech A/S has a twelve month low of $1.70 and a twelve month high of $22.05.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.